In a landmark resolution, the global pharmaceutical company Novartis has reached a settlement with the estate of Henrietta Lacks, ending litigation that accused the firm of unjustly profiting from her "stolen" cells. The agreement, finalised this month in federal court in Maryland, addresses claims that Novartis commercialised the revolutionary HeLa cell line without compensating Lacks' descendants, despite the cells' incalculable role in advancing modern medicine.
The Legacy of HeLa Cells and the Legal Battle
The lawsuit, filed in 2024, sought from Novartis "the full amount of its net profits obtained by commercialising the HeLa cell line," which originated from cells taken from Lacks' cervical tumour without her knowledge in 1951. At the time, Lacks was a 31-year-old mother of five undergoing treatment for cervical cancer at Johns Hopkins Hospital, where doctors preserved a sample of her cancer cells during a biopsy. Unlike most cell samples, her cells not only survived but thrived in laboratory conditions, becoming the first immortalised human cell line that scientists could cultivate indefinitely.
A Foundation for Medical Breakthroughs
HeLa cells have been a cornerstone of scientific research, enabling countless medical innovations over the decades. Their contributions include the development of the polio vaccine, genetic mapping techniques, and even COVID-19 vaccines. Despite this profound impact on global health, the Lacks family received no compensation for decades, highlighting ethical concerns within the biomedical industry. In a joint statement, the Lacks family and Swiss-based Novartis expressed that they are "pleased they were able to find a way to resolve this matter filed by Henrietta Lacks' Estate outside of court," though details of the settlement remain confidential.
Broader Legal Context and Ongoing Cases
This settlement marks the second such agreement for the Lacks estate, following an undisclosed settlement with biotechnology company Thermo Fisher Scientific Inc. in 2023. Lawyers for the family argued in that case that Thermo Fisher continued to commercialise HeLa cell products long after the origins of the cell line became widely known, unjustly enriching itself. The estate's legal actions accuse biomedical businesses of benefiting from a historically racist medical system that exploited Black patients like Lacks, who was buried in an unmarked grave after her death.
Other lawsuits remain active, including cases against Ultragenyx Pharmaceutical and Viatris, filed in Baltimore federal court. Attorneys for the Lacks family have indicated that additional complaints may be forthcoming, suggesting a growing effort to seek accountability and restitution for the commercial use of HeLa cells. Johns Hopkins Hospital has stated that it never sold or profited from the cell lines, but numerous companies have patented methods for using them, leading to ongoing legal scrutiny.
The Human Story Behind the Science
Henrietta Lacks was a poor tobacco farmer from southern Virginia who moved with her husband to Turner Station, a historically Black community near Baltimore. Her story gained widespread attention through Rebecca Skloot's bestselling book, "The Immortal Life of Henrietta Lacks," published in 2010, and an HBO film adaptation where Oprah Winfrey portrayed her daughter. The narrative not only underscores the scientific marvel of HeLa cells but also the personal toll on the Lacks family, some of whom faced chronic illnesses without health insurance, despite the cells' global contributions.
The immortal nature of HeLa cells allowed researchers worldwide to conduct reproducible studies using identical cells, revolutionising fields from oncology to virology. However, this scientific progress came at the cost of ethical oversight, as Lacks' consent was never obtained. The recent settlements reflect a shifting landscape where legal systems are increasingly addressing historical injustices in medical research, potentially setting precedents for future cases involving biological materials and patient rights.
